IceCure Medical Ltd. (NASDAQ:ICCM) Receives $2.64 Average Price Target from Analysts

IceCure Medical Ltd. (NASDAQ:ICCM) has earned an average rating of “Moderate Buy” from the five research firms that are presently covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell rating, one has given a hold rating, two have assigned a buy rating and one has issued a strong buy rating on the company. The average 12 month price objective among analysts that have issued ratings on the stock in the last year is $2.6350.

A number of analysts have recently commented on the company. Zacks Research cut IceCure Medical from a “strong-buy” rating to a “hold” rating in a research report on Friday, August 15th. HC Wainwright upped their target price on shares of IceCure Medical from $2.00 to $2.50 and gave the company a “buy” rating in a report on Tuesday, October 7th. Brookline Capital Management restated a “buy” rating on shares of IceCure Medical in a research report on Wednesday, August 13th. Weiss Ratings restated a “sell (e+)” rating on shares of IceCure Medical in a research report on Wednesday, October 8th. Finally, Loop Capital set a $2.77 price target on IceCure Medical in a research report on Wednesday, August 13th.

IceCure Medical Stock Down 4.9%

ICCM opened at $0.71 on Tuesday. The business’s 50-day simple moving average is $0.96 and its 200-day simple moving average is $1.00. The company has a debt-to-equity ratio of 0.02, a quick ratio of 0.88 and a current ratio of 1.18. IceCure Medical has a one year low of $0.53 and a one year high of $1.66. The stock has a market capitalization of $48.78 million, a P/E ratio of -4.44 and a beta of 0.31.

IceCure Medical (NASDAQ:ICCM) last posted its earnings results on Wednesday, August 13th. The company reported $0.06 EPS for the quarter, topping analysts’ consensus estimates of ($0.06) by $0.12. IceCure Medical had a negative return on equity of 136.96% and a negative net margin of 317.62%.The business had revenue of $0.66 million for the quarter, compared to analysts’ expectations of $0.90 million. Analysts anticipate that IceCure Medical will post -0.28 EPS for the current year.

About IceCure Medical

IceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and marketing of cryoablation systems, disposables, and technologies for treating tumors. The company offers ProSense system, a single probe system for the treatment of tumors, as well as associated disposables; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology.